ganciclovir

(redirected from Cytovene)
Also found in: Medical.
Related to Cytovene: Ganciclovir sodium

gan·ci·clo·vir

 (găn-sī′klō-vîr′, -klə-)
n.
A synthetic nucleoside analog, C9H13N5O4, derived from guanine and used in the prevention and treatment of opportunistic cytomegalovirus infections.

[gan-, origin unknown + -ciclovir, antiviral drug suffix (from acyclovir).]
Translations

ganciclovir

n ganciclovir m
References in periodicals archive ?
Currently, only two drugs, Cytovene and Foscavir, are commonly used for treatment of HHV-6.
Valcyte is the organ pro-drug of Roche's Cytovene (ganciclovir), the most widely prescribed anti-CMV medication in the world.
Examples of these drugs include Zovirax (acyclovir) or its generic version acyclovir, Valtrex (valacyclovir), Cytovene (ganciclovir), Valcyte (valgancyclovir), and Vistide (cidofovir).
Valcyte, the oral pro-drug of Cytovene (ganciclovir), is the most widely prescribed anti-CMV medication in the United States.
Valcyte is an oral prodrug, or improved formulation, of Cytovene (ganciclovir), which has been widely used to prevent CMV for the past 15 years.
Valcyte delivers the same active drug ingredient as Cytovene oral with up to 10 times greater bioavailability than Cytovene.
However, the availability of ganciclovir from Valcyte is ten times greater than the availability of ganciclovir from Cytovene capsules and Valcyte has a more convenient dosing regimen.
In addition, an ongoing clinical trial, conducted by Roche Laboratories, is studying Vitrasert in combination with oral Cytovene, recently approved for the prevention of CMV disease.
His experience in product launch is evidenced by products such as TORADOL, TICLID, Synerel and Cytovene.
Valganciclovir is the pro-drug of CYTOVENE (ganciclovir), also made by Roche, which is currently the most widely prescribed anti-CMV medication worldwide.
Clinical studies have repeatedly shown the benefit of the intravenous and oral form of Cytovene (ganciclovir) in the treatment of CMV retinitis.